ArticleFrontiers in chemistry2025
Unveiling the material basis of Shenshuaifu granule and its therapeutic mechanism in chronic renal failure: a combined approach of high-resolution mass spectrometry and
Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic renal failure (CRF) is a serious state of continuous development in various chronic renal diseases. Shenshuaifu granule is a hospital preparation of Chinese medicines used at Shenzhen Traditional Chinese Medicine Hospital. It has been reported to delay the progression of renal failure in clinical application, but its material basis and mechanism are still unclear. Methods: In this study, ultra-high-performance liquid chromatography tandem with Q-Exactive-Orbitrap mass spectrometry (UHPLC-QE-MS), network pharmacology, and molecular docking technology were used to rapidly explore the plant metabolites of Shenshuaifu granule and its potential mechanisms. Results: The results showed that a total of 56 plant metabolites were identified from Shenshuaifu granule, including nine prototype metabolites detected in rat plasma after administration. Through network pharmacology and molecular docking technology, the plant metabolites that enter the blood from Shenshuaifu granule may regulate key targets, such as TNF, SRC, STAT3, EGFR, BCL2, JUN, and PTGS2. The GO and KEGG enrichment analysis showed that the AGE-RAGE signaling pathway, HIF-1 signaling pathway, and TNF signaling pathway were the main mechanisms of Shenshuaifu granule in the treatment of CRF. Conclusion: Flavonoids and quinones in Shenshuaifu granule are potential active plant metabolites, suggesting anti-inflammatory, anti-glomerulosclerosis, and fibrosis effects on CRF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.